Clinical outcome and tolerability of sertraline in major depression
| Autor: | Sergio Manfré, V. Laini, Massimo C. Mauri, G. Panza, Francesca Regispani, Marta E. Scalvini, L. Boscati, Lara Malvini, L.S. Volonteri, Giancarlo Cerveri |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Pharmacology
Sertraline medicine.medical_specialty book.periodical Nausea Hamilton Rating Scale for Depression medicine.disease Tolerability Cephalalgia Rating scale Internal medicine Anesthesia Brief Psychiatric Rating Scale medicine Major depressive disorder medicine.symptom Psychology book Biological Psychiatry medicine.drug |
| Zdroj: | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 26:597-601 |
| ISSN: | 0278-5846 |
| DOI: | 10.1016/s0278-5846(01)00314-1 |
| Popis: | Sertraline (SRT) has been shown to be an effective antidepressant in extensive clinical trial programs but data on plasma concentrations regarding clinical outcome and tolerability are lacking. Twenty-one out-patients of both sexes, with mean age of 50.23 years (S.D. = 17.37), affected by major depressive disorder, recurrent (Diagnostic and Statistical Manual of Mental Disorder--IV, DSM-IV), were treated with 25-150 mg of SRT once a day (mean=66.26 mg, S.D.=30.50) for 30 days. Clinical evaluation was assessed at baseline (T0), after 15 days (T15), and then after 30 days (T30). Plasma samples for SRT level determination were collected at T30. Brief Psychiatric Rating Scale (BPRS), Hamilton Rating Scale for Depression (HRS-D), and Hamilton Rating Scale for Anxiety (HRS-A) showed a significant improvement during the study (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect